Dracen Pharmaceuticals
Glutamine Inhibition for Oncology

Dracen Pharmaceuticals is developing cancer therapeutics by targeting glutamine metabolism with a pro-drug of a previously known glutamine analog called DON. Pro-drug allows selective intracellular release in tumors and eliminates DON’s toxic gastrointestinal effects. In addition to direct tumor effects, DON pro-drugs are able to stimulate the immune system which allows its use in combination with checkpoint inhibitors.


University
Johns Hopkins University
Sector
Life Science
Status
Active
Initial Investment Stage
Early
View Website